Neuren Pharmaceuticals (ASX:NEU) Tax Provision : A$-48.1 Mil (TTM As of Dec. 2023)

View and export this data going back to 2005. Start your Free Trial

What is Neuren Pharmaceuticals Tax Provision?

Neuren Pharmaceuticals's tax provision for the six months ended in Dec. 2023 was A$-46.2 Mil. Its tax provision for the trailing twelve months (TTM) ended in Dec. 2023 was A$-48.1 Mil.

Neuren Pharmaceuticals Tax Provision Historical Data

The historical data trend for Neuren Pharmaceuticals's Tax Provision can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Neuren Pharmaceuticals Tax Provision Chart

Neuren Pharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Tax Provision

Get a 7-Day Free Trial

-48.06

Neuren Pharmaceuticals Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Tax Provision	Get a 7-Day Free Trial															-	-	-	-1.82	-46.24

Neuren Pharmaceuticals Tax Provision Calculation

Tax to be paid.

Tax Provision for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$-48.1 Mil.

Neuren Pharmaceuticals (ASX:NEU) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Neuren Pharmaceuticals Ltd (ASX:NEU) » Definitions » Tax Provision

Comparable Companies

Traded in Other Exchanges

NURPF:USA

Address

697 Burke Road, Suite 201, Camberwell, Melbourne, VIC, AUS, 3124

Website

https://www.neurenpharma.com

Neuren Pharmaceuticals Ltd is a biopharmaceutical company, which engages in the development of new therapies for brain injury, neurodevelopment, and neurodegenerative disorders. Its drugs target symptoms resulting from acute traumatic brain injury, as well as symptoms of chronic conditions, such as Rett syndrome and Fragile X syndrome.